4//SEC Filing
Harmon Cyrus 4
Accession 0001415889-24-015508
CIK 0001750284other
Filed
Jun 3, 8:00 PM ET
Accepted
Jun 4, 9:00 PM ET
Size
9.8 KB
Accession
0001415889-24-015508
Insider Transaction Report
Form 4
Harmon Cyrus
Director
Transactions
- Sale
Common Stock
2024-06-03$10.93/sh−5,000$54,650→ 786,283 total - Sale
Common Stock
2024-06-04$12.33/sh−5,000$61,650→ 781,283 total - Sale
Common Stock
2024-05-31$9.41/sh−15,000$141,150→ 791,283 total
Holdings
- 122,028(indirect: See Footnote)
Common Stock
Footnotes (5)
- [F1]The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person dated May 16, 2023.
- [F2]The weighted average sale price for the transaction reported was $9.41, and the range of prices was between $9.34 and $9.56. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.
- [F3]The weighted average sale price for the transaction reported was $10.93, and the range of prices was between $10.91 and $11.01. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.
- [F4]The weighted average sale price for the transaction reported was $12.33, and the range of prices was between $12.23 and $12.43. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.
- [F5]The shares are held by the Harmon Family Investors LLC, of which the Reporting Person is the manager.
Documents
Issuer
Olema Pharmaceuticals, Inc.
CIK 0001750284
Entity typeother
Related Parties
1- filerCIK 0001831410
Filing Metadata
- Form type
- 4
- Filed
- Jun 3, 8:00 PM ET
- Accepted
- Jun 4, 9:00 PM ET
- Size
- 9.8 KB